Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19863575 | 0.88 | CPB1 (0.48) | CPB1ALDH1A1GAATSHRSMN1; SMN2 | |
| SCHEMBL20991956 | 0.88 | CPB1 (0.48) | CPB1ALDH1A1GAATSHRSMN1; SMN2 | |
| SCHEMBL19857404 | 0.85 | KDM1A (0.34) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL30330711 | 0.84 | CPB1 (0.43) | CPB1ALDH1A1GAATSHRSMN1; SMN2 | |
| SCHEMBL31644552 | 0.82 | CPB1 (0.46) | CPB1ALDH1A1GAATSHRSMN1; SMN2 | |
| SCHEMBL30330926 | 0.81 | CPB1 (0.42) | CPB1ALDH1A1GAATSHRSMN1; SMN2 | |
| SCHEMBL30233895 | 0.80 | CPB1 (0.48) | CPB1ALDH1A1GAATSHRSMN1; SMN2 | |
| SCHEMBL28897095 | 0.80 | CPB1 (0.48) | CPB1ALDH1A1GAATSHRSMN1; SMN2 | |
| SCHEMBL29483860 | 0.80 | CPB1 (0.46) | CPB1ALDH1A1GAATSHRSMN1; SMN2 | |
| SCHEMBL3367621 | 0.79 | KDM1A (0.45) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324872-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324872-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CPB1 2326/4885ALDH1A1 3720/4885GAA 3247/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CPB1 2326/4885ALDH1A1 3720/4885GAA 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.